Results 191 to 200 of about 1,040 (258)

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, Volume 13, Issue 31, 4 June 2026.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Welfare of beef cattle. [PDF]

EFSA J
EFSA Panel on Animal Health and Welfare (AHAW), Nielsen SS, Alvarez J, Boklund A, Dippel S, Dorea F, Figuerola J, Herskin MS, Michel V, Miranda Chueca MA, Nannoni E, Nonno R, Riber AB, Stahl K, Stegeman JA, Thulke HH, Tuyttens F, Cozzi G, Knierim U, Martí S, Mullan S, Ashe S, Cecchinato G, Lima E, Mosbach-Schulz O, Vitali M, Zanna MB, Winckler C.   +27 more
europepmc   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

A measurement framework to assess software maturity models. [PDF]

PeerJ Comput Sci
Alshareef R, Alshayeb M, Niazi M, Mahmood S.   +3 more
europepmc   +1 more source

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, Volume 13, Issue 35, 24 June 2026.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source

Corrigendum to "Decision support systems for waste-to-energy technologies: A systematic literature review of methods and future directions for sustainable implementation in Ghana" [Heliyon Volume 11, Issue 3, February 2025, Article e42353]. [PDF]

Heliyon
Adu TF, Mensah LD, Rockson MAD, Kemausuor F.   +3 more
europepmc   +1 more source

ERP implementation planning : a critical success factors (CSFs) approach

, 2014
openaire   +2 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, Volume 13, Issue 35, 24 June 2026.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Translational interdisciplinary research on human chorionic gonadotropin's enhancement of neuroendocrine crosstalk: a novel medical hypothesis for systemic adjunctive treatment of psychiatric disorders. [PDF]

Front Psychiatry
Gaspary JFP, Lopes LFD, Camara AG.
europepmc   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, Volume 13, Issue 33, 15 June 2026.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source